Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 445 of 3330
Next
>>
>
11101 to 11125 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
ZR75B	HR+	Luminal	Bortezomib	Proteasome	Proteasome	6.67	uM	7555.074	0.2037	-0.2294	1.6682
ZR75B	HR+	Luminal	Bortezomib	Proteasome	Proteasome	6.67	uM	7555.074	0.2037	-0.2294	1.6682
ZR75B	HR+	Luminal	Bortezomib	Proteasome	Proteasome	33.3	uM	7555.074	0.1454	-0.3705	1.6682
ZR75B	HR+	Luminal	Bortezomib	Proteasome	Proteasome	33.3	uM	7555.074	0.1454	-0.3705	1.6682
ZR75B	HR+	Luminal	Bortezomib	Proteasome	Proteasome	167	uM	7555.074	0.1137	-0.4568	1.6682
ZR75B	HR+	Luminal	Bortezomib	Proteasome	Proteasome	167	uM	7555.074	0.1137	-0.4568	1.6682
184A1	NM	Basal	Bosutinib	Src	nRTK	0.0000853	uM	12509.17	1.0001	1.0001	1.3955
184A1	NM	Basal	Bosutinib	Src	nRTK	0.000427	uM	12509.17	0.8152	0.7276	1.3955
184A1	NM	Basal	Bosutinib	Src	nRTK	0.00213	uM	12509.17	0.9837	0.9766	1.3955
184A1	NM	Basal	Bosutinib	Src	nRTK	0.0107	uM	12509.17	0.9959	0.9941	1.3955
184A1	NM	Basal	Bosutinib	Src	nRTK	0.0533	uM	12509.17	1.0318	1.0453	1.3955
184A1	NM	Basal	Bosutinib	Src	nRTK	0.267	uM	12509.17	0.7939	0.6952	1.3955
184A1	NM	Basal	Bosutinib	Src	nRTK	1.33	uM	12509.17	0.4537	0.1353	1.3955
184A1	NM	Basal	Bosutinib	Src	nRTK	6.67	uM	12509.17	0.3966	0.0310	1.3955
184A1	NM	Basal	Bosutinib	Src	nRTK	33.3	uM	12509.17	0.3415	-0.0739	1.3955
184B5	NM	Basal	Bosutinib	Src	nRTK	0.0000853	uM	12566.17	0.9506	0.9320	1.4648
184B5	NM	Basal	Bosutinib	Src	nRTK	0.000427	uM	12566.17	0.9546	0.9375	1.4648
184B5	NM	Basal	Bosutinib	Src	nRTK	0.00213	uM	12566.17	1.0045	1.0061	1.4648
184B5	NM	Basal	Bosutinib	Src	nRTK	0.0107	uM	12566.17	0.9527	0.9349	1.4648
184B5	NM	Basal	Bosutinib	Src	nRTK	0.0533	uM	12566.17	0.9464	0.9262	1.4648
184B5	NM	Basal	Bosutinib	Src	nRTK	0.267	uM	12566.17	0.8060	0.7262	1.4648
184B5	NM	Basal	Bosutinib	Src	nRTK	1.33	uM	12566.17	0.4619	0.1804	1.4648
184B5	NM	Basal	Bosutinib	Src	nRTK	6.67	uM	12566.17	0.2287	-0.2696	1.4648
184B5	NM	Basal	Bosutinib	Src	nRTK	33.3	uM	12566.17	0.2210	-0.2865	1.4648
600MPE	HR+	Luminal	Bosutinib	Src	nRTK	0.000256	uM	12224.145	0.9703	0.9391	0.9737

|<
<<
Previous
Page 445 of 3330
Next
>>
>
11101 to 11125 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)